Pharmaceuticals News and Research

RSS

U.S. should continue funding maternal health programs in Afghanistan as troop drawdown begins

The success of the Afghan Safe Birth Project, funded by HHS, and the Community Midwife Education program, supported by USAID, in helping reduce maternal mortality in Afghanistan "is in jeopardy - not because of security threats, but because of a fiscal one," authors Isobel Coleman and Gayle Tzemach Lemmon, both fellows at the Council on Foreign Relations, write in a Bloomberg opinion piece.

9 Aug 2011

PHT total revenues increase 10% for first half of 2011

PHT Corporation completed its most successful Q2 in company history on June 30, 2011. The strong, outstanding results reflect the growing worldwide adoption of its market-leading ePRO Systems.

9 Aug 2011

K-V sells assets of Nesher to Zydus and Zynesher Pharmaceuticals

K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc., the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals (USA) LLC.

9 Aug 2011

Eurofins Optimed, Spaulding Clinical announce joint partnership agreement

Eurofins Optimed Clinical Research, an experienced European clinical research service provider and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a joint partnership agreement.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

HUYA enters strategic partnership with King's Lab

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.

8 Aug 2011

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress.

8 Aug 2011

Response Genetics second quarter total revenue increases 18.8% to $6.7 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

8 Aug 2011

AMRI second quarter total revenue increases 9% to $53.9 million

AMRI today reported financial and operating results for the second quarter ended June 30, 2011.

8 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

ADVENTRX's second quarter net loss decreases to $4.4 million

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the periods ended June 30, 2011.

8 Aug 2011

Insmed second quarter revenues decrease to $1.0 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011.

8 Aug 2011

Keryx reports net loss of $3.1 million for second quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease, today announced its results for the second quarter ended June 30, 2011.

8 Aug 2011

U.S. District Court rules in favor of POZEN in Treximet patent litigation

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.

8 Aug 2011

Affymetrix announces commercialization of next-generation human transcriptome array

Affymetrix, Inc. today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies.

8 Aug 2011

Medicare prescriptions premiums expected to decrease for seniors

According to an Obama administration announcement last Thursday as the health costs continue to rise, Medicare beneficiaries will see the average price of a Part D drug plan decline slightly next year. This is expected to offer some relief amid pressure to cut the federal health insurance program for the elderly.

8 Aug 2011

Zuellig Pharma, ADEC Solutions enter new KPO joint venture

ADEC Solutions, an end-to-end business process outsourcing (BPO) global market provider of customized outsourcing solutions, announced a partnership agreement with Zuellig Pharma, uniting the two companies to create a global pharmaceutical and healthcare-focused knowledge process outsourcing (KPO) and BPO powerhouse.

8 Aug 2011

Sebelius, Berwick tout drop in Medicare Rx costs

Even as health costs continue to rise, Medicare beneficiaries will see the average price of a Part D drug plan decline slightly next year, the Obama administration announced Thursday, offering some relief amid pressure to cut the federal health insurance program for the elderly.

6 Aug 2011